Upcoming webinar

Driving clinical trial strategy with MRD-powered RWD and AI

Date: Wednesday, May 20, 2026

Time: 10:00 AM PT | 1:00 PM ET

Webinar duration: 45 minutes

Registrants will receive a recording of the webinar approximately one week after the event.

At Natera, we believe the integration of best-in-class molecular diagnostics, real world evidence, technology and AI lead to life-changing care.

Molecular residual disease (MRD) provides an early, quantitative signal of disease burden. When captured throughout the course of disease progression across the patient journey.

Natera’s unique, real-world molecular database combines longitudinal, multi-timepoint MRD data with continuously refreshed clinical insights across early- and late-stage settings, powering both advanced analytics and clinical decision making tools.

Join our Data and AI experts to learn how biopharma teams are applying these solutions to drive more informed trial strategies.

In this webinar, we’ll discuss how to:

Use MRD-driven insights to assess treatment response earlier in development
Interrogate molecular RWD to refine trial design, feasibility, and cohort selection
Apply AI-driven approaches to characterize patients and disease risk more efficiently
Translate RWD and AI insights into actionable development strategies, with recent case examples.

The webinar will conclude with a Q&A section with the speakers.

Natera Honey Pot

Register Now:

First Name*

Last Name*

Email Address*

Job Title*

Phone*

Company Name*

Postal Code*

Country*

I am a*

Do you have any questions for the presenters that you would like to submit before the webinar?

Please fill in the field above only if you have specific questions. Otherwise, leave it blank.

Natera would like to send you information about our products and services. You may unsubscribe from these communications at any time.

Our speakers

Matt Love, VP

Business Development

RWD and AI, Natera

Leading biopharma partnerships in RWD & AI
Former leader at Tempus with deep experience in genomics, data, and drug development
MBA, Pharmaceutical & Healthcare Marketing, Bachelors, BA, Saint Joseph’s University

Jenny Park, Sr. Director

Product Development

RWD and AI, Natera

Leading development of data platforms integrating molecular and clinical insights
Former product leader at Illumina and Ancestry with deep experience in genomics, data platforms, and analytics
BS, University of California, Berkeley

Erik Bergstrom, PhD

Machine Learning Scientist

Natera

Machine learning scientist focused on multimodal AI for precision oncology
Develops AI models integrating histopathology, genomics, and ctDNA for prediction and risk stratification
PhD, UC San Diego with postdoctoral training in cancer genomics and biomarkers

The tests described have been developed and their performance characteristics determined by the CLIA-certified laboratory performing the tests. The tests have not been cleared or approved by the US Food and Drug Administration (FDA). CAP accredited, ISO 13485 certified, and CLIA certified. © 2026 Natera, Inc. All Rights Reserved.

13011 McCallen Pass, Building A Suite 100 | Austin, TX 78753 | natera.com | Do Not Share My Personal Information | Privacy Policy